Solid Biosciences Inc. (SLDB) Key Metrics
SLDB valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $593.0M
- Enterprise value
- $500.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.6
- Price / book
- 2.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.47
SLDB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSLDB valuation Price multiples at each fiscal year-end price.
SLDB returns How much profit the business earns on the capital it uses.
SLDB per-share figures Results divided by the shares outstanding at year-end.
SLDB financial health Debt, liquidity and how easily interest is covered.
SLDB efficiency & capital use Working capital cycle and where the cash goes.
SLDB valuation history
SLDB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SLDB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SLDB cash returned to shareholders
SLDB price vs earnings per share
SLDB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $493.5M | $163.3M | — | — | — | — | — | — | — | — |
| Enterprise value | $326.8M | $38.5M | — | — | — | — | — | — | — | — |
| Price / book | 2.7 | 1.2 | — | — | — | — | — | — | — | — |
| Earnings yield | −35.3% | −76.4% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −31.9% | −61.7% | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.3% | 3.1% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $5.64 | $4.00 | $6.14 | $5.38 | $26.25 | $113.70 | $66.75 | $402.00 | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Earnings per share | −$1.99 | −$3.06 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.79 | −$2.45 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.80 | −$2.47 | — | — | — | — | — | — | — | — |
| Cash per share | $2.15 | $3.65 | — | — | — | — | — | — | — | — |
| Book value per share | $2.06 | $3.36 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $2.06 | $3.36 | — | — | — | — | — | — | — | — |
| Capex per share | $0.01 | $0.02 | — | — | — | — | — | — | — | — |
| Debt per share | $0.24 | $0.59 | — | — | — | — | — | — | — | — |
| Shares outstanding | 87.5M | 40.8M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +114.4% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −109.9% | −94.6% | −56.8% | −41.0% | −42.4% | −83.2% | −114.2% | −226.9% | — | — |
| Return on invested capital (ROIC) | — | −492.6% | −296.5% | −580.3% | — | — | — | — | — | — |
| Return on assets (ROA) | −82.8% | −70.5% | −45.2% | −34.9% | −35.8% | −64.3% | −96.5% | −69.3% | −89.2% | −44.7% |
| Return on tangible assets | −75.0% | −66.1% | −58.2% | −33.0% | −31.1% | −51.6% | −113.3% | −53.6% | −68.4% | −53.0% |
| Free cash flow margin | — | — | — | — | −580.4% | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $21.2M | $24.2M | $26.3M | $28.5M | $2.1M | $5.2M | $7.1M | $1.9M | — | — |
| Cash & short-term investments | $187.8M | $148.9M | $123.6M | $213.7M | $207.8M | $154.7M | $83.5M | $122.5M | $69.1M | $37.7M |
| Net debt | −$166.7M | −$124.7M | −$97.4M | −$185.2M | −$205.7M | −$149.6M | −$76.5M | −$120.6M | −$69.1M | −$37.7M |
| Debt / equity | 0.12 | 0.18 | 0.21 | 0.13 | 0.01 | 0.04 | 0.09 | 0.02 | — | — |
| Debt / assets | 0.09 | 0.13 | 0.16 | 0.11 | 0.01 | 0.03 | 0.07 | 0.01 | — | — |
| Current ratio | 6.14 | 5.20 | 8.94 | 9.76 | 9.43 | 6.49 | 4.72 | 10.31 | 6.27 | 5.82 |
| Quick ratio | 6.14 | 5.20 | 8.94 | 9.76 | 9.18 | 6.49 | 4.72 | 10.31 | 6.27 | 5.82 |
| Interest coverage | — | -381.6 | -237.1 | -5.2 | — | — | — | — | — | — |
| Working capital | $172.0M | $127.0M | $115.2M | $197.1M | $199.0M | $134.4M | $68.0M | $116.2M | $59.4M | $33.1M |
| Invested capital | $13.3M | $12.5M | $29.1M | $26.5M | $2.5M | −$17.5M | $3.6M | $4.6M | −$128.4M | −$122.0M |
| Tangible asset value | $180.0M | $137.2M | $126.5M | $211.7M | $208.2M | $132.1M | $80.0M | $125.2M | −$59.3M | −$37.9M |
| Net current asset value | $152.9M | $105.9M | $91.3M | $171.1M | $198.4M | $119.8M | $62.9M | $114.2M | −$64.8M | −$38.5M |
| Graham net-net per share | $1.55 | $2.39 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | $1.7M | $5.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | — | — | — | 37.2% | 9.4% | 27.0% | — | — | — | — |
| Capex / depreciation | 0.70 | 0.27 | 0.59 | 1.25 | 0.43 | 0.23 | 1.55 | 4.97 | 5.08 | 7.00 |
| Stock-based compensation / revenue | — | — | — | 93.1% | 98.2% | 348.7% | — | — | — | — |
| R&D / revenue | — | — | — | 968.9% | 431.3% | 1,945.5% | — | — | — | — |
| SG&A / revenue | — | — | — | 357.6% | 199.2% | 647.1% | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | 2.5 | 1.5 | 0.0 | — | — | — | — |
| Days of inventory on hand | — | — | — | — | 740.7 | — | — | — | — | — |
| Days payables outstanding | 832.3 | 466.0 | 372.6 | 583.7 | 476.4 | 483.8 | 698.9 | 1,020.5 | 3,279.3 | 11,706.1 |
| Cash conversion cycle (days) | — | — | — | -581.2 | 265.8 | -483.8 | — | — | — | — |
| Receivables turnover | — | — | — | 147.16 | 247.64 | — | — | — | — | — |
| Payables turnover | 0.44 | 0.78 | 0.98 | 0.63 | 0.77 | 0.75 | 0.52 | 0.36 | 0.11 | 0.03 |
| Inventory turnover | — | — | — | — | 0.49 | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.03 | 0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | $55,000 | $55,000 | $0 | — | — | — | — |
| Average payables | $3.7M | $3.1M | $2.6M | $3.9M | $3.9M | $5.2M | $5.4M | $4.4M | $4.0M | $1.8M |
| Average inventory | — | — | — | — | $6.0M | — | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SLDB's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SLDB valuation and financial ratios
Solid Biosciences earned a return on equity of −109.9% in fiscal 2025. It ended the year with $21.2 million of debt and $187.8 million in cash and short-term investments, a net cash position of $166.7 million. It returned $1.7 million to shareholders: $0 in dividends and $1.7 million in share buybacks.
See the SLDB income statement, the SLDB chart for price history, or the SLDB stock overview for the latest quote and news.
SLDB key metrics FAQ
What is Solid Biosciences's return on equity?
Solid Biosciences's return on equity (ROE) was −109.9% in fiscal 2025: net income of -$174.3 million on average shareholders' equity of $158.6 million.
How much debt does Solid Biosciences have?
Solid Biosciences had total debt of $21.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.12 and more cash than debt.
Does Solid Biosciences buy back its shares?
Yes. Solid Biosciences spent $1.7 million on net share repurchases in fiscal 2025 Shares outstanding changed +114.4% over the year, to 87.5M..
What is Solid Biosciences's free cash flow yield?
Solid Biosciences generated -$157.4 million of free cash flow in fiscal 2025, a free cash flow yield of −31.9% on its market value at year-end ($493.5 million).
What is Solid Biosciences's current ratio?
Solid Biosciences's current ratio was 6.14 at the end of fiscal 2025: current assets were 6.14 times current liabilities.